



For personal use only

| Results for announcement to the market | | |
|--|--|--|
| Name of issuer | Ryman Healthcare Limited | |
| Reporting Period | 12 months to 31 March 2026 | |
| Previous Reporting Period | 12 months to 31 March 2025 (restated) | |
| Currency | NZD | |
| | Amount (000s) | Percentage change |
| Revenue from continuing operations | \$855,590 | 12.47% |
| Total Revenue | \$855,590 | 12.47% |
| Net profit/(loss) from continuing operations | \$(171,345) | -66.65% |
| Total net profit/(loss) | \$(171,345) | -66.65% |
| Interim/Final Dividend | | |
| Amount per Quoted Equity Security | No dividend is to be paid for the 12 months ended 31 March 2026. | |
| Imputed amount per Quoted Equity Security | N/A | |
| Record Date | N/A | |
| Dividend Payment Date | N/A | |
| | Current period | Prior comparable period |
| Net tangible assets per Quoted Equity Security (in dollars and cents per security) | \$4.005 | \$4.106 (31 March 2025 restated) \$4.182 (31 March 2025 reported) |
| A brief explanation of any of the figures above necessary to enable the figures to be understood | Prior comparative periods have been restated to align with changes to the Group's financial reporting. Refer to note 1 of the Consolidated Financial Statements for explanation. | |
| Authority for this announcement | | |
| Name of person authorised to make this announcement | Morgan Powell | |
| Contact person for this announcement | Matt Prior | |
| Contact phone number | +64 3 366 4069 | |
| Contact email address | matt.prior@rymanhealthcare.com | |
| Date of release through MAP | 26 May 2026 | |